BR112022004378A2 - Vacinas para vírus lassa - Google Patents
Vacinas para vírus lassaInfo
- Publication number
- BR112022004378A2 BR112022004378A2 BR112022004378A BR112022004378A BR112022004378A2 BR 112022004378 A2 BR112022004378 A2 BR 112022004378A2 BR 112022004378 A BR112022004378 A BR 112022004378A BR 112022004378 A BR112022004378 A BR 112022004378A BR 112022004378 A2 BR112022004378 A2 BR 112022004378A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- flavivirus
- sequence
- lassa virus
- terminus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
vacinas para vírus lassa. a presente invenção refere-se a polinucleotídeos compreendendo uma sequência de um flavivírus atenuado, infeccioso, vivo, onde uma sequência de nucleotídeo codificando pelo menos u ma parte de uma proteína glicoproteína de arenavírus está localizada na região intergênica entre o gene e e ns1 de dito flavivírus, de modo que um vírus quimérico é expresso, caracterizado em que a sequência codificada no c-terminal da proteína e de dito flavivírus e no n-terminal do peptídeo sinal da proteína ns1 de dito flavivírus compreende na seguinte ordem: - ainda um peptídeo sinal de uma proteína ns1 de flavivírus, - uma proteína glicoproteína de arenavírus carecendo de sequência sinal n-terminal e o domínio transmembrana de gp2, - domínios tm1 e tm2 de uma proteína e flaviviral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197202 | 2019-09-13 | ||
| PCT/EP2020/075541 WO2021048402A1 (en) | 2019-09-13 | 2020-09-11 | Lassavirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022004378A2 true BR112022004378A2 (pt) | 2022-06-07 |
Family
ID=68137784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004378A BR112022004378A2 (pt) | 2019-09-13 | 2020-09-11 | Vacinas para vírus lassa |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220378903A1 (pt) |
| EP (1) | EP4041300A1 (pt) |
| JP (1) | JP2022547695A (pt) |
| CN (1) | CN114728054A (pt) |
| AU (1) | AU2020346382A1 (pt) |
| BR (1) | BR112022004378A2 (pt) |
| WO (1) | WO2021048402A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005042014A1 (en) | 2003-10-29 | 2005-05-12 | The University Of Queensland | West nile virus vaccine |
| GB201307528D0 (en) | 2013-04-26 | 2013-06-12 | Univ Leuven Kath | Bacterial artificial chromosomes |
| BR102016018430A2 (pt) * | 2016-08-10 | 2018-02-27 | Fundação Oswaldo Cruz | Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos. |
| US20200171141A1 (en) * | 2017-07-18 | 2020-06-04 | Geovax, Inc. | Compositions and Methods for Generating an Immune Response to LASV |
-
2020
- 2020-09-11 CN CN202080071104.5A patent/CN114728054A/zh active Pending
- 2020-09-11 BR BR112022004378A patent/BR112022004378A2/pt unknown
- 2020-09-11 US US17/642,795 patent/US20220378903A1/en active Pending
- 2020-09-11 AU AU2020346382A patent/AU2020346382A1/en active Pending
- 2020-09-11 JP JP2022516041A patent/JP2022547695A/ja active Pending
- 2020-09-11 WO PCT/EP2020/075541 patent/WO2021048402A1/en unknown
- 2020-09-11 EP EP20767710.5A patent/EP4041300A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728054A (zh) | 2022-07-08 |
| US20220378903A1 (en) | 2022-12-01 |
| JP2022547695A (ja) | 2022-11-15 |
| EP4041300A1 (en) | 2022-08-17 |
| WO2021048402A1 (en) | 2021-03-18 |
| AU2020346382A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| Hu et al. | Rotavirus non-structural proteins: structure and function | |
| EP2970393B1 (en) | Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| JP2016501015A5 (ja) | デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用 | |
| BR112017022298A2 (pt) | geranilgeranil pirofosfato sintase | |
| ATE516346T1 (de) | Herstellung und verwendungen von chimäre glykosyltransferasen mit optimierter glykosylierungsaktivität codierenden gensequenzen | |
| JP2009261399A5 (pt) | ||
| MX339277B (es) | Agente inductor de inmunidad. | |
| HRP20231581T1 (hr) | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima | |
| BRPI0504945B1 (pt) | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos | |
| MX2008011728A (es) | Virus de enfermedad de newcastle recombinante que expresa hemaglutinina h5 de virus de influenza aviar. | |
| FI3436591T3 (fi) | Adenoviruksen kuoriproteiinista johdetut kuljetusvälineet | |
| BR112022004378A2 (pt) | Vacinas para vírus lassa | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| BR112022001075A2 (pt) | Proteína l1 do papilomavírus quimérico | |
| WO2023056351A8 (en) | Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof | |
| AR072156A1 (es) | Proteinas de fusion y su aplicacion para la preparacion de vacunas contra la hepatitis c y b | |
| CA2938921A1 (en) | Codon-optimized nucleotide sequence encoding mg53, its recombinants and use thereof | |
| RU2009115688A (ru) | Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды | |
| WO2008152652A3 (en) | A dengue envelope domain iii-based tetravalent protein vaccine | |
| MX2023012595A (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv. | |
| JP2019534241A5 (pt) | ||
| JP2017526366A5 (pt) | ||
| CA3181996A1 (en) | Sars-cov-2 inhibitors |